Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

Sicurezza ed efficacia dell'aripiprazolo nel trattamento di mantenimento a lungo termine dei pazienti pediatrici con irritabilità associata a disturbo autistico

The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

215

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alabama
      • Dothan, Alabama, Stati Uniti, 36303
        • Harmonex Neuroscience Research, Inc
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006
        • Southwest Autism Research And Resource Center
    • California
      • Costa Mesa, California, Stati Uniti, 92626
        • Clinical Innovations, Inc.
      • Glendale, California, Stati Uniti, 91206
        • Behavioral Research Specialists, Llc
      • Palo Alto, California, Stati Uniti, 94306
        • Abbey Neuropsychology Clinic
      • San Francisco, California, Stati Uniti, 94143
        • Ucsf - Lppi
      • Stanford, California, Stati Uniti, 94305
        • Stanford University School Of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Children'S National Medical Center
    • Florida
      • Gainesville, Florida, Stati Uniti, 32607
        • Sarkis Clinical Trials
      • Hialeah, Florida, Stati Uniti, 33012
        • Palm Springs Research Institute
      • Maitland, Florida, Stati Uniti, 32751
        • Florida Clinical Research Center, Llc
      • Miami, Florida, Stati Uniti, 33155
        • Miami Children'S Hospital
      • Tampa, Florida, Stati Uniti, 33613
        • University Of South Florida
    • Georgia
      • Smyrna, Georgia, Stati Uniti, 30080
        • Institute For Behavioral Medicine, Llc
    • Idaho
      • Coeur d'Alene, Idaho, Stati Uniti, 83814
        • Kootenai Behavioral Health Center
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • Kosair Charities Pediatric Clinical Research Unit
    • Louisiana
      • Shreveport, Louisiana, Stati Uniti, 71103
        • Lsu Health Sciences Center
    • Massachusetts
      • Newton, Massachusetts, Stati Uniti, 02459
        • Neurocare, Inc.
    • Michigan
      • Bloomfield Hills, Michigan, Stati Uniti, 48302
        • Neurobehavioral Medicine Group
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Center For Psychiatry And Behavioral Medicine, Inc
    • New Jersey
      • Gibbsboro, New Jersey, Stati Uniti, 08026
        • Clinical Research Center Of New Jersey
      • Toms River, New Jersey, Stati Uniti, 08755
        • Children'S Specialized Hosp
    • New York
      • Stony Brook, New York, Stati Uniti, 11794
        • Stony Brook University School Of Medicine
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27517
        • Unc Chapel Hill
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • University Hospitals Case Medical Center
      • Cleveland, Ohio, Stati Uniti, 44104
        • Cleveland Clinic
      • Columbus, Ohio, Stati Uniti, 43210
        • The Ohio State University Nisonger Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73116
        • Cutting Edge Research Group
      • Oklahoma City, Oklahoma, Stati Uniti, 73117
        • Ou Physician'S Child Study Center
      • Tulsa, Oklahoma, Stati Uniti, 74104
        • Tulsa Clinical Research, Llc
    • Oregon
      • Gresham, Oregon, Stati Uniti, 97030
        • Cyn3rgy Research
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19124
        • Drexel University College Of Medicine
      • Pittsburgh, Pennsylvania, Stati Uniti, 15203
        • Western Psychiatric Institute And Clinic
    • Tennessee
      • Kingsport, Tennessee, Stati Uniti, 37660
        • Holston Medical Group
    • Texas
      • DeSoto, Texas, Stati Uniti, 75115
        • Insite Clinical Research
    • Utah
      • Clinton, Utah, Stati Uniti, 84015
        • Ericksen Research And Development
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23510
        • Childrens Specialty Gr., Pllc
      • Richmond, Virginia, Stati Uniti, 23298
        • Virginia Treatment Center For Children

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 6 anni a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  • Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
  • Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
  • Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
  • Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
  • An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
  • Mental age of at least 24 months

Key Exclusion Criteria:

  • Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
  • Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
  • Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
  • Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
  • History of neuroleptic malignant syndrome
  • At significant risk for suicide based on history or routine psychiatric status examination
  • A seizure within the past year
  • History of severe head trauma or stroke
  • History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
  • Weight lower than 15 kg
  • Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
  • History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Tablets, oral, 0 mg, once daily, 16 weeks

Sperimentale: Aripiprazolo

Tablets, oral, 2-15 mg, once daily, 13-42 weeks

Altri nomi:
  • Abilitare
  • BMS-337039

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Patients Relapsing by Week 16
Lasso di tempo: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment.

From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Lasso di tempo: From Baseline (end of Phase 1) to Week 16 of Phase 2

ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Lasso di tempo: From Baseline (end of Phase 1) to Week 16 of Phase 2

CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly.

From Baseline (end of Phase 1) to Week 16 of Phase 2
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
Lasso di tempo: Up to 26 weeks

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Up to 26 weeks

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
Lasso di tempo: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Weekly from Weeks 1 through 16 (end of treatment) of Phase 2

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 marzo 2011

Completamento primario (Effettivo)

20 giugno 2012

Completamento dello studio (Effettivo)

20 giugno 2012

Date di iscrizione allo studio

Primo inviato

22 ottobre 2010

Primo inviato che soddisfa i criteri di controllo qualità

22 ottobre 2010

Primo Inserito (Stimato)

25 ottobre 2010

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi